Overview

Over the past ten years the pharmaceutical industry has investigated the development of drugs from biological molecules, e.g. proteins, which, due to their complexity, has been enabled by the very rapid advances in mass spectrometry (MS) and experimental approaches. This book provides a review of the state of the art for the in-depth characterization of these complex treatment modalities. Coverage focuses on the use of mass spectrometry for the assessment of alternative modes of drug efficacy and their quality alongside the inclusion of information on the use of MS in the development of protein biosimilars. Providing a unique and up to date addition to the literature in this area, this book is aimed at researchers, both new and established, looking into the applications of MS in the pharmaceutical industry.

Full Product Details

9781782629757

Table of Contents

Reviews

Author Information

Mark Bolgar completed his PhD at the University of Manchester in 1997. He is now a Senior Research Fellow in the Drug Product Science and Technology Department of Bristol-Myers Squibb in New Brunswick, New Jersey. He currently leads the New Modalities and Biologics Team which supports formulation development of biologics and acts as a centre of excellence for the analytical development of new drug modalities such as peptides, ADCs and oligonucleotides. Having been involved in the application of mass spectrometry for more than 30 years, he has authored or co-authored 35 papers on the use of mass spectrometry in the areas of natural product identification, peptide characterization, identification and quantitation of drug impurities, bioanalysis, ambient ionization, and the characterization of conjugated proteins. He is also a co-inventor of a patented technique for ambient ionization mass spectrometry.

Tab Content 6

Customer Reviews

Recent Reviews

Countries Available